Booming Regeneron adds to R&D footprint in NY

With sales of eye drug Eylea growing at breakneck pace and a couple of promising candidates in its pipeline, Regeneron ($REGN) needs some more space. Monday, it launched construction of a 300,000-square-foot R&D facility at its campus in Westchester County, NY. The company plans to move its scientists to the new center in 2015; in the meantime, they'll be working on expanding Eylea's label and bringing rheumatoid arthritis and cholesterol prospects to market. More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.